The comparison of our results with the outcomes obtained by other authors allowed us to conclude that HMGB1 measurement may be useful in the assessment of clinical management of GBM patients on condition that the management includes chemo- and radiotherapy and the ensuing inflammatory conditions and necrosis [81,84,85]. The gene discussed is HMGB1; the disease is glioblastoma.